TMPRSS2: ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia

Journal of Clinical Oncology

Volumn 32, Issue 3, 2014, Pages 206-211

  Park, Kyung ^a   Dalton, James T ^b   Narayanan, Ramesh ^b   Barbieri, Christopher E ^a   Hancock, Michael L ^b   Bostwick, David G ^c   Steiner, Mitchell S ^b   Rubin, Mark A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GTx   (United States)

^c BOSTWICK LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TOREMIFENE; TRANSMEMBRANE PROTEASE SERINE 2 TRANSCRIPTION FACTOR ERG FUSION PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ONCOPROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; GENE FUSION; GENE OVEREXPRESSION; GLEASON SCORE; HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; VERY ELDERLY; BIOPSY; CANCER GRADING; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; UPREGULATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TOREMIFENE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84897019741     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8386     Document Type: Article

References (29)

1. American Cancer Society: Cancer facts and figures. http://www.cancer.org/ research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
2. Bostwick DG, Cheng L: Precursors of prostate cancer. Histopathology 60:4-27, 2012
3. Bostwick DG, Liu L, Brawer MK, et al: High-grade prostatic intraepithelial neoplasia. Rev Urol 6:171-179, 2004
4. De Matteis M, Poggi C, De Martino A, et al: Repeat biopsy in patients with initial diagnosis of PIN. Radiol Med 110:190-198, 2005 (Pubitemid 41666008)
5. Epstein JI, Herawi M: Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol 175:820-834, 2006 (Pubitemid 43199991)
6. Bostwick DG, Qian J: High-grade prostatic intraepithelial neoplasia. Mod Pathol 17:360-379, 2004 (Pubitemid 41646613)
7. Tomlins SA, Mehra R, Rhodes DR, et al: TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66:3396-3400, 2006
8. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005 (Pubitemid 41528150)
9. Perner S, Mosquera JM, Demichelis F, et al: TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 31:882-888, 2007 (Pubitemid 47165141)
10. Carver BS, Tran J, Gopalan A, et al: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41:619-624, 2009
11. Han B, Mehra R, Lonigro RJ, et al: Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22:1083-1093, 2009
12. Mosquera JM, Perner S, Genega EM, et al: Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14:3380-3385, 2008
13. Setlur SR, Mertz KD, Hoshida Y, et al: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100:815-825, 2008 (Pubitemid 351809667)
14. Demichelis F, Fall K, Perner S, et al: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596-4599, 2007 (Pubitemid 47037039)
15. Han B, Mehra R, Dhanasekaran SM, et al: A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68:7629-7637, 2008
16. Esgueva R, Perner S, LeFargue C, et al: Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 23:539-546, 2010
17. Pflueger D, Rickman DS, Sboner A, et al: N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11:804-811, 2009
18. Taneja SS, Morton R, Barnette G, et al: Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 31:523-529, 2013
19. Park K, Tomlins SA, Mudaliar KM, et al: Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12:590-598, 2010
20. McNeal JE, Bostwick DG: Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 17:64-71, 1986 (Pubitemid 16163546)
21. Loeb S, Carter HB, Berndt SI, et al: Complications after prostate biopsy: Data from SEER-Medicare. J Urol 186:1830-1834, 2011
22. Wagenlehner FM, van Oostrum E, Tenke P, et al: Infective complications after prostate biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63:521-527, 2013
23. Steiner MS: High grade prostatic intraepithelial neoplasia is a disease. Curr Urol Rep 2:195-198, 2001
24. Gao X, Li LY, Zhou FJ, et al: ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis. Clin Cancer Res 18:4163-4172, 2012
25. He H, Osunkoya AO, Carver P, et al: Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): Lack of utility to stratify cancer risks associated with HGPIN. BJU Int 110:E751-E755, 2012
26. Marshall JR, Tangen CM, Sakr WA, et al: Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 4:1761-1769, 2011
27. Andriole GL, Bostwick DG, Brawley OW, et al: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202, 2010
28. Fleshner NE, Kapusta L, Donnelly B, et al: Progression from high-grade prostatic intraepithelial neoplasia to cancer: A randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol 29:2386-2390, 2011
29. Bostwick DG, Ma J: Over-diagnosis of high-grade prostatic intraepithelial neoplasia: A prospective study of 251 cases. BJU Int 100:1036-1039, 2007 (Pubitemid 47537667)